Latest News and Press Releases

Regeneron is renewing it's sponsorship of the Science Talent Search for the next 10 years, committing $150 million.

NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome

MONTRÉAL, 26 févr. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », la «Société », « nous » ou « notre ») (TSXV : LOVE) (OTCQX : LOVFF) (FRA : 8CB0), producteur verticalement...

Cannara (LOVE) graduates to the TSX on March 2, 2026, enhancing visibility, liquidity and institutional access; TD Cowen initiated coverage Feb 24

Over 1.1 million total VOQUEZNA® prescriptions filled to date $57.6 million in Q4 net revenues; $175.1 million in FY 2025 net revenues, a 217% increase from FY 2024 Q4 operating expenses of...

PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for 2026 in patients with metabolic and fibrotic diseaseCarmel Nanthakumar,...

InnoCare announced key clinical development progress, including the completion of patient enrollment of multiple Phase III registrational trials.

The Stock Markets are opening with a strong crosscurrent of AI-powered drug discovery, cross-border biologics distribution, and capital structure resets

MUNICH, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The 20th annual BIO-Europe Spring is heading to Lisbon, Portugal, from March 23–25, 2026, with a digital experience to follow on March 31–April 1. For the...

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines to treat brain disorders and symptoms caused by...